Immunogenicity, Vaccine
7
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
29%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (7)
Study Interchangeability Hep-B Vaccine Administered at Birth Dose
A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece
COVID-19 Quantitative Antibody Titers & Booster Vaccinations
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
Seroprevalence of Pertussis Among Children and Adolescents in Croatia
Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules